{"organizations": [], "uuid": "534841bc60ed760cbbf031e70de358b0d1379aa7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/johnsonjohnson-patent-remicade/u-s-appeals-court-invalidates-jj-patent-on-remicade-idUSL2N1PI11C", "country": "US", "domain_rank": 408, "title": "U.S. appeals court invalidates J&J patent on Remicade", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-23T17:50:00.000+02:00", "replies_count": 0, "uuid": "534841bc60ed760cbbf031e70de358b0d1379aa7"}, "author": "", "url": "https://www.reuters.com/article/johnsonjohnson-patent-remicade/u-s-appeals-court-invalidates-jj-patent-on-remicade-idUSL2N1PI11C", "ord_in_thread": 0, "title": "U.S. appeals court invalidates J&J patent on Remicade", "locations": [], "entities": {"persons": [{"name": "jan wolfe", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "j&j", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "johnson & johnson", "sentiment": "none"}, {"name": "u.s. circuit court of appeals for the federal circuit", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 23, 2018 / 3:51 PM / Updated 14 minutes ago U.S. appeals court invalidates J&J patent on Remicade Reuters Staff 1 Min Read \nJan 23 (Reuters) - A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&Jâ€™s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug. \nThe U.S. Circuit Court of Appeals for the Federal Circuit affirmed a ruling by a U.S. administrative court that a J&J patent covering the active ingredient in Remicade was invalid because it was based on an obvious concept. (Reporting by Jan Wolfe)", "external_links": [], "published": "2018-01-23T17:50:00.000+02:00", "crawled": "2018-01-23T18:07:19.011+02:00", "highlightTitle": ""}